Validation Data Shows Rosetta's Array-based CUP Test Outperforms PCR-based Predecessor
June 28, 2011
Validation Data Shows Rosetta's Array-based CUP Test Outperforms PCR-based Predecessor
Data from the study showed that Rosetta's array-based Mets 2 test has 88 percent concordance with clinical presentation and pathology, exceeding the accuracy of the PCR-based version of the test.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Pathwork's Economics Study Finds TOO Test 'Strongly' Cost-Effective in Extending Survival
January 18, 2012 / Pharmacogenomics Reporter - New York State Clears Rosetta Genomics' Array-based Cancer of Unknown Primary Test
December 13, 2011 / BioArray News - Rosetta Gets NY State Approval for Tumor Test
December 9, 2011 / GenomeWeb Daily News - Rosetta Genomics to Intensify Marketing Outreach for Menu of miRview Microarray Tests
April 2, 2013 / BioArray News - Startup Twistnostics Developing Rapid Microarray Platform for PGx and Infectious Disease Assays
March 26, 2013 / BioArray News